Get the Stockscreener App
120.67
1.10%
-1.34
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $120.67, with a volume of 135.85K.
It is down -1.10% in the last 24 hours and up +2.82% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$122.01
Open:
$123.02
24h Volume:
135.85K
Relative Volume:
1.35
Market Cap:
$2.28B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
48.08
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
+0.56%
1M Performance:
+2.82%
6M Performance:
+13.75%
1Y Performance:
+66.05%
1-Day Range:
$119.02
$123.02
1-Week Range:
$117.63
$123.02
52-Week Range:
$67.72
$129.90
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
120.67 | 2.28B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Rice Hall James & Associates LLC Sells 7,954 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Allspring Global Investments Holdings LLC Decreases Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals (LGND) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Sold by Acuitas Investments LLC - MarketBeat
Villere ST Denis J & Co. LLC Has $30.76 Million Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Allspring Global Investments Holdings LLC Cuts Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Acquired by Congress Asset Management Co. - MarketBeat
Louisiana State Employees Retirement System Increases Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Yousif Capital Management LLC Has $771,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Armenian Reporter
Yousif Capital Management LLC Has $771,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Purchased by State of Alaska Department of Revenue - Defense World
Stephens Investment Management Group LLC Sells 5,914 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
abrdn plc Sells 72,509 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
SG Americas Securities LLC Purchases New Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Bought by Chicago Capital LLC - MarketBeat
Molluscum Contagiosum Market Expected to rise, 2034 | Verrica Pharmaceuticals, Novan and Ligand Pharmaceuticals, Veloce Biopharma, expected to drive market - Barchart
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
BlackRock, Inc. Reduces Stake in Ligand Pharmaceuticals Inc. - GuruFocus.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Hantz Financial Services Inc. Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Looking Back On Ligand Pharmaceuticals (NASDAQ:LGND) - Seeking Alpha
Court Place Advisors LLC Sells 7,700 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Investors in Ligand Pharmaceuticals (NASDAQ:LGND) have seen decent returns of 53% over the past year - Simply Wall St
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Burney Co. Grows Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
JPMorgan Chase & Co. Lowers Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Position Lowered by JPMorgan Chase & Co. - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Recommendation of “Buy” by Brokerages - Defense World
LGND (Ligand Pharmaceuticals) Debt-to-EBITDA : 0.54 (As of Sep. 2024) - GuruFocus.com
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Don't Ignore The Insider Selling In Ligand Pharmaceuticals - Simply Wall St
Principal Financial Group Inc. Boosts Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Is Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Recent Price Movement Underpinned By Its Weak Fundamentals? - Simply Wall St
Jane Street Group LLC Sells 7,790 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Jane Street Group LLC Trims Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Octavio Espinoza Executes Sell Order: Offloads $244K In Ligand Pharmaceuticals Stock - Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2024 Earnings Guidance - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) shareholders have earned a 59% return over the last year - Yahoo Finance
MML Investors Services LLC Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: Octavio Espinoza Sells Shares of Ligand Pharmaceuticals Inc (LGND) - GuruFocus.com
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) CFO Octavio Espinoza Sells 2,104 Shares - MarketBeat
Ligand Pharmaceuticals CFO Espinoza sells $244,850 in stock By Investing.com - Investing.com Canada
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):